Clinical Trials/NL-OMON26301

NL-OMON26301

Recruiting

Not Applicable

Primary prevention of rheumatoid arthritis.

Prof.dr. B.A.C. DijkmansVUMC/Jan van Breemen Instituut0 sites80 target enrollmentTBD

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Not specified
Sponsor: Prof.dr. B.A.C. DijkmansVUMC/Jan van Breemen Instituut
Enrollment: 80
Status: Recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

Arthritis Rheum 2004; 50: 380-6
Arthritis Rheum 2004; 50: 2423-7

Registry

who.int

Start Date

TBD

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Investigators

Sponsor

Prof.dr. B.A.C. DijkmansVUMC/Jan van Breemen Instituut

Eligibility Criteria

Inclusion Criteria

•1\. Age 18\-70 years for RF\+, 18\+ for aCCP\+;
•2\. Twice increased IgM\-RF and/or anti\-CCP with 4\+ weeks interval;

Exclusion Criteria

•Situations with possible false positive RF:

Outcomes

Primary Outcomes

Not specified

Similar Trials

Primary prevention of rheumatoid arthritisRheumatoid arthritisMusculoskeletal Diseases

ISRCTN73232918Jan van Breemen Instituut (Netherlands)80

Not yet recruiting

Prevention of RA by B cell directed therapy.pre-clinical RA

NL-OMON28176Academic Medical Center/University of Amsterdam, Amsterdam90

Active, not recruiting

Prevention of clinically manifest rheumatoid arthritis by B cell directed therapy in the earliest phase of the disease.

EUCTR2009-010955-29-NLDivision of Clinically Immunology and Rheumatology, AMC

BeSt, BehandelStrategieën in Reumatoïde Artritis.

NL-OMON24149Dutch College of Health Insurance Companies508

Arthritis Prevention In the Pre-clinical Phase of Rheumatoid Arthritis with AbataceptTopic: Musculoskeletal disordersSubtopic: Musculoskeletal (all Subtopics)Disease: MusculoskeletalMusculoskeletal Diseases

ISRCTN46017566Guy's and St Thomas' NHS Foundation Trust213